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responders, all of whom had a KIT D816V mutation at any 
time, mast cell infiltration and tryptase level decreased by 
70 % and 29.8 %, respectively; absolute neutrophil count 
increased by 94.7 %. Laboratory parameters also improved 
in the non-ASM subgroups. Overall survival at 24 months 
was 81.2 % (95 % CI 70.6–91.8 %) with median survival 
not yet reached. New or worsening grade 3/4 hematologic 
adverse events (AEs) included thrombocytopenia (10.3 %), 
anemia (10.0 %), and neutropenia (6.9 %). The most com-
mon grade 3/4 nonhematologic drug-related AEs were diar-
rhea (6.6 %) and headache (4.9 %). Eleven patients (9 with 
ASM, 2 with MCL) died, 10 due to progressive disease; 7 
deaths occurred ≥28 days after treatment discontinuation.
Conclusions Nilotinib 400 mg twice daily was effective 
in some patients with SM, including patients with mutated 
KIT D816V.
Keywords Nilotinib · Tyrosine kinase inhibitor · 
Systemic mastocytosis · KIT D816V · Aggressive systemic 
mastocytosis · Indolent systemic mastocytosis
Introduction
Systemic mastocytosis (SM) is a myeloproliferative neo-
plasm characterized by the proliferation and activation 
of mast cells in various organs, including the skin, liver, 
spleen, and hematopoietic tissues, eventually resulting in 
impaired organ function (Valent et al. 2003). The clinical 
course in SM is heterogeneous and ranges from asympto-
matic with a normal life expectancy to highly aggressive 
with decreased life expectancy (Quintas-Cardama et al. 
2011). SM is rare; the annual incidence of new cases is 0.3 
per 100,000 (Woodward 2003). The median overall sur-
vival is approximately 63 months overall, 198 months for 
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Purpose Activating KIT mutations are part of the patho-
genesis of systemic mastocytosis (SM). Nilotinib is a 
tyrosine kinase inhibitor that potently inhibits activated 
forms of KIT. This phase 2, open-label, single-arm study 
(CAMN107A2101; www.clinicaltrials.gov NCT00109707) 
evaluated nilotinib in patients with SM.
Methods Patients with SM [aggressive SM (ASM), indo-
lent SM, or other] received nilotinib 400 mg twice daily. 
C-findings were collected retrospectively to assess response 
using criteria proposed after trial initiation. Response 
was evaluated using improvements in laboratory findings 
(for all patients) and ASM response criteria (for the ASM 
subgroup).
Results In 61 patients enrolled, the median nilo-
tinib exposure was 232 days (range 3–1274 days) with a 
median follow-up of 34.7 months. In patients with ASM 
(n = 37), the overall response rate was 21.6 %. In the eight 
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patients with indolent SM (ISM), 24 months for patients 
with aggressive SM (ASM), and 2 months for patients with 
mast cell leukemia (MCL) (Lim et al. 2009b; Fuller 2012).
SM is classified based on the abnormal morphology, 
immunophenotype, and molecular characteristics of mast 
cells. The diagnostic algorithm for SM includes evaluat-
ing bone marrow by immunostaining for the presence of 
tryptase and/or KIT and immunophenotyping mast cells 
for expression of CD25 and/or CD2. Serum tryptase level 
and the presence of the KIT D816V mutation in blood or 
bone marrow are also evaluated. SM is then categorized as 
ISM (2 or more B-findings), ASM (1 or more C-findings), 
or MCL (at least 20 % mast cells on bone marrow aspirate 
smear) (Pardanani 2015; Horny et al. 2008).
There is no accepted standard therapy for patients with 
SM. Patients generally receive treatments intended to man-
age symptoms and improve quality of life, such as anti-
histamines for the relief of pruritus and flushing, proton 
pump inhibitors to treat gastrointestinal symptoms, or cor-
ticosteroids and/or analgesics for mitigating bone pain and 
other symptoms (Andersen et al. 2012; Valent et al. 2010; 
Pardanani 2015). Patients with advanced SM may receive 
treatment with interferon (IFN)-α or cladribine; these treat-
ments also decrease symptoms but may not substantially 
reduce mast cell burden (Verstovsek 2013). Tyrosine kinase 
inhibitors (TKIs), such as imatinib, have demonstrated 
modest effects in SM, although primary resistance is com-
mon in patients with the KIT D816V mutation (Lim et al. 
2009a; Pardanani 2012; Valent et al. 2010).
As many as 93 % of SM cases may harbor an activating 
D816V mutation in the catalytic domain of KIT (Garcia-
Montero et al. 2006; Quintas-Cardama et al. 2011; Akin 
and Metcalfe 2004), a receptor tyrosine kinase expressed 
on the surface of mature mast cells and mast cell precursors 
(Lammie et al. 1994; Valent et al. 2003). The KIT D816V 
mutation induces downstream signaling that is independ-
ent of the KIT ligand stem cell factor (Furitsu et al. 1993) 
and is mediated through the signal transducer and activator 
of transcription 5 (STAT5) and phosphoinositol-3-kinase 
(PI3K) pathways (Harir et al. 2008). Constitutive KIT acti-
vation results in increased mast cell accumulation in the 
bone marrow and more aggressive disease (Valent et al. 
2003; Lim et al. 2009b; Verstovsek 2013). The presence of 
the KIT D816V mutation is one of four minor criteria for 
the diagnosis of SM (Valent et al. 2003), and KIT D816V 
allele burden can be used to monitor residual disease in 
patients with SM (Erben et al. 2014). Additional KIT muta-
tions as well as KIT-independent pathways (e.g., Lyn and 
Btk) have recently been implicated in the pathogenesis of 
SM (Gleixner et al. 2011; Schwaab et al. 2013; Orfao et al. 
2007).
The TKI nilotinib was rationally designed to inhibit 
mutant forms of the BCR-ABL protein that display 
resistance to the TKI imatinib in patients with chronic 
myeloid leukemia (CML); both imatinib and nilotinib are 
approved for the treatment of CML. Nilotinib is also active 
against the KIT kinase in vitro (Weisberg et al. 2005; Man-
ley et al. 2010). Recent data from a multicenter, phase 2, 
open-label registration trial demonstrated that nilotinib 
400 mg twice daily continued to be safe and effective in 
patients with CML in chronic phase (Giles et al. 2013), 
accelerated phase (le Coutre et al. 2012), and blast crisis 
(Giles et al. 2012) who were resistant to or intolerant of 
prior therapies. Based on promising results from the first 
data analysis (Hochhaus et al. 2006), we evaluated the effi-
cacy and safety of nilotinib 400 mg twice daily in patients 
with SM (with or without the D816V mutation) enrolled in 
the phase 2 nilotinib registration trial (CAMN107A2101, 
registered at www.clinicaltrials.gov as NCT00109707).
Materials and methods
Patient population
Enrollment criteria for the phase 2, multicenter 2101 trial 
have been previously described (H. M. Kantarjian et al. 
2007). Briefly, adult patients with hematologic malignan-
cies were recruited into 6 parallel treatment arms. Patients 
who met the standard disease criteria for SM (at least 1 
major and 1 minor or 3 minor criteria for SM) (Valent et al. 
2003) and needed treatment were recruited into the SM 
arm of the study and were assessed for efficacy according 
to a Simon two-stage minimax design (Simon 1989). The 
major criterion for SM is the presence of multifocal clus-
ters of mast cells in the bone marrow. The minor criteria 
are the presence of spindle-shaped mast cells in the mar-
row, elevated serum tryptase levels, abnormal expression of 
CD2 or CD25, and the presence of the KIT D816V muta-
tion (Valent et al. 2001). Key inclusion criteria included 
World Health Organization (WHO) performance status ≤2. 
Exclusion criteria included disease infiltration into the cen-
tral nervous system and impaired cardiac function (includ-
ing a left ventricular ejection fraction <45 %, congenital 
long QT syndrome, or QTc >450 ms).
Recruitment occurred between June 9, 2005, and March 
31, 2006. Data on the significance of improvements in 
clinical findings (C-findings) as a measure of treatment 
response and clear definitions of the various types of SM 
were published after initiation of the study (Gotlib et al. 
2013; Horny et al. 2008). To incorporate these data into 
the study, C-findings were collected, and patients were cat-
egorized as having ASM, ISM, or other SM subtype retro-
spectively based on WHO criteria for these SM subtypes 
(Horny et al. 2008). Per the WHO criteria, patients meeting 
SM criteria who had one or more C-findings were classified 
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as having ASM as long as the criteria for MCL were not 
met.
Informed consent was obtained from all patients accord-
ing to institutional guidelines. The study was conducted in 
accordance with the Declaration of Helsinki; the protocol 
and all amendments were reviewed and approved by the 
ethics board or institutional review board at each participat-
ing trial center.
Dosing
Nilotinib 400 mg twice daily was selected as the study 
dose based on safety and tolerability and pharmacokinetic 
and preliminary efficacy data from the phase 1 portion of 
this study (H. Kantarjian et al. 2006). One treatment cycle 
consisted of 28 days of continuous dosing with nilotinib 
400 mg twice daily. Patients remained on nilotinib treat-
ment until disease progression or unacceptable toxic-
ity that precluded additional therapy. Patients responding 
to therapy were allowed to enter an extension study after 
24 months of treatment and continue receiving drug.
Dose modifications, including dose reductions and dose 
interruptions, were allowed for patients who developed 
intolerance to nilotinib. Patients with treatment interrup-
tions longer than 21 days were discontinued from the study, 
except those with hematologic toxicity, in whom interrup-
tions were permitted for up to 42 days. Patients discon-
tinuing due to adverse events (AEs) were monitored until 
resolution or stabilization of the AE. All patients were mon-
itored for AEs for 28 days after the final dose of nilotinib.
Study objectives
The primary efficacy endpoint was the overall response rate 
(ORR), defined as the proportion of patients with a minor 
response or better lasting a minimum of 4 weeks (Valent 
et al. 2003). Response was evaluated using improvements 
in laboratory findings (for all patients) and ASM response 
criteria (for the ASM subgroup). For patients with ASM, 
response evaluations were based on findings in bone mar-
row, peripheral blood, and extramedullary sites of dis-
ease and improvements in C-findings (Valent et al. 2007). 
C-findings were defined as hematologic abnormalities 
[absolute neutrophil count (ANC) <1.0 × 109/L, hemo-
globin level <10 g/dL, or platelet count <100 × 109/L], 
hepatomegaly with ascites and impaired liver function, por-
tal hypertension, palpable splenomegaly with hypersplen-
ism, malabsorption with hypoalbuminemia and/or weight 
loss, and skeletal lesions (such as large-sized osteolyses 
and/or severe osteoporosis with pathological fracture). 
The definitions of complete or incomplete remission and 
pure clinical response included complete resolution of 1 
C-finding and no progression in other C-findings. Complete 
remission also required disappearance of organomegaly, 
decrease of serum tryptase level to <20 ng/mL, and loss 
of all mast cell infiltrates in affected organs. Incomplete 
remission required >50 % decrease in serum tryptase level 
and/or a decrease in mast cell infiltrates and/or visible 
reduction of organomegaly. Pure clinical response involved 
no response in mast cell infiltrates, serum tryptase level, or 
organomegaly. Good partial response was defined as >50 % 
regression in ≥1 C-findings and no progression in other 
C-findings. Minor response was defined as ≤50 % regres-
sion of ≥1 C-findings and no progression in other C-find-
ings. Stable disease was defined by C-finding parameters 
falling within a constant range. Progressive disease was 
defined as ≥1 C-finding with progression.
Secondary efficacy endpoints included overall survival, 
which was estimated using the Kaplan–Meier method. 
The analysis of overall survival included all deaths occur-
ring during treatment or after discontinuation of study 
drug. Assessment of KIT mutation status was performed by 
Sanger sequencing after polymerase chain reaction (PCR) 
amplification, and FIP1L1–PDGFRA translocation status 
was determined by nested reverse-transcriptase PCR at 
baseline and/or at various time points throughout the study. 
The ORR stratified by KIT D816V mutation status at base-
line or at any time was assessed.
Laboratory parameters were assessed to help character-
ize the quality of response in responders in the ASM sub-
group and in all patients with other SM subtypes. For each 
laboratory parameter, values were recorded at baseline and 
the time of best response. The “best value” was the lowest 
level of tryptase and mast cell burden and the highest level 
for other parameters. The median baseline and best value 
were calculated for the responder population. The differ-
ence between these median values was then used to deter-
mine the percentage improvement in each parameter.
Toxicity was assessed using the National Cancer Insti-
tute Common Terminology Criteria for Adverse Events 
(NCI CTCAE) version 3.0 (National Cancer Institute 
2006). AEs, serious AEs (SAEs), and hematologic and non-
hematologic laboratory abnormalities were assessed.
Results
Patient characteristics
Baseline demographic and disease characteristics of the 61 
patients enrolled in the SM arm of the 2101 study are listed 
in Table 1. Patients were retrospectively assigned to SM 
subgroups based on WHO 2008 criteria (Tefferi and Var-
diman 2008). The patient population was heterogeneous. 
Most patients had ASM [n = 37 (60.7 %)] or ISM [n = 19 
(31.1 %)]; of the 5 remaining patients, 3 had MCL, 1 had 
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Table 1  Characteristics of all patients and responders
Total ASM ISM Othera
All patients  
(N = 61)




All patients  
(n = 19)
All patients  
(n = 5)
Characteristics at baseline
 Median age (range, years) 52 (29–79) 49 (29–79) 55 (41–79) 50 (33–78) 66 (52–67)
 Male, n (%) 34 (55.7) 21 (56.8) 3 (37.5) 11 (57.9) 2 (40.0)
 Entry criteria for SM, n (%)
  Major + 1 minor criteria 49 (80.3) 29 (78.4) 8 (100) 16 (84.2) 4 (80.0)
  Three minor criteria 11 (18.0) 8 (21.6) 0 2 (10.5) 1 (20)
  Otherb 1 (1.6) 0 0 1 (5.3) 0
 No prior treatment, n (%) 29 (47.5) 15 (40.5) 1 (12.5) 10 (52.6) 4 (80.0)
 WHO performance status, n (%)
  Grade 0 26 (42.6) 15 (40.5) 1 (12.5) 9 (47.4) 2 (40.0)
  Grade 1 25 (41.0) 14 (37.8) 6 (75.0) 9 (47.7) 2 (40.0)
  Grade 2 8 (13.1) 6 (16.2) 0 1 (5.3) 1 (20.0)
  Grade >2 1 (1.6) 1 (2.7) 1 (12.5) 0 0
  Missing 1 (1.6) 1 (2.7) 0 0 0
 Median time since diagnosis of SM 
(range, months)
25.9 (1.2–287.3) 25.9 (1.2–287.3) 34.5 (9.2–84.8) 27.4 (1.6–123.4) 8.34 (3.1–77.6)
 Time since SM diagnosis, n (%)
  <6 months 13 (21.3) 10 (27.0) 0 2 (10.5) 1 (20.0)
  6 months to <1 year 8 (13.1) 3 (8.1) 1 (12.5) 3 (15.8) 2 (40.0)
  1 to <2 years 8 (13.1) 5 (13.5) 1 (12.5) 3 (15.8) 0
  2 to <5 years 13 (21.3) 9 (24.3) 3 (37.5) 3 (15.8) 1 (20.0)
  ≥5 years 19 (31.1) 10 (27.0) 3 (37.5) 8 (42.1) 1 (20.0)
KIT D816V mutation status, n (%)
 At baselinec
  Yes 36 (59.0) 22 (59.5) 6 (75.0) 10 (52.6) 4 (80.0)
  No 5 (8.2) 2 (5.4) 0 3 (15.8) 0
  Missing 20 (32.8) 13 (35.1) 2 (25.0) 6 (31.6) 1 (20.0)
 At any time
  Yes 48 (78.7) 29 (78.4) 8 (100) 15 (78.9) 4 (80.0)
  No 13 (21.3) 8 (21.6) 0 4 (21.1) 1 (20.0)
  Missing 0 0 0 0 0
Laboratory values at baseline
 Tryptase level, ng/mL (n = 54) (n = 33) (n = 7) (n = 16) (n = 5)
  <20 4 (7.4) 3 (9.1) 1 (14.3) 1 (6.3) 0
  20–100 18 (33.3) 8 (24.2) 1 (14.3) 8 (50.0) 2 (40.0)
  >100–200 19 (35.2) 13 (39.4) 2 (28.6) 5 (31.3) 1 (20.0)
  >200 13 (24.1) 9 (27.3) 3 (42.9) 2 (12.5) 2 (40.0)
 Hemoglobin level (g/dL)
  <10 7 (11.5) 7 (18.9) 2 (25.0) 0 0
  10–15 47 (77.0) 26 (70.3) 6 (75.0) 16 (84.2) 5 (100)
  >15 7 (11.5) 4 (10.8) 0 3 (15.8) 0
  Albumin level (g/dL)
  <3.4 7 (11.5) 5 (13.5) 2 (25.0) 0 2 (40.0)
  3.4–5.4 54 (88.5) 32 (86.5) 6 (75.0) 19 (100) 3 (60.0)
  >5.4 0 0 0 0 0
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SM-acute myeloid leukemia (AML), and 1 had SM with an 
associated clonal hematologic non–mast cell lineage dis-
ease (AHNMD). At study entry, 49 patients (80.3 %) met 
1 major and 1 minor disease criteria for SM; 11 patients 
(18.0 %) met 3 minor criteria for SM; and 1 patient (1.6 %) 
had a major protocol violation, defined as entering the 
study but not meeting the predefined SM disease group 
classification. In the ASM group (n = 37), C-findings were 
as follows: 15 patients had skeletal involvement only; 11 
patients had cytopenias only; 3 patients had hepatospleno-
megaly only; 3 patients had skeletal lesions accompanied 
by hepatosplenomegaly; and 5 patients had malabsorp-
tion, skeletal lesions, and hepatosplenomegaly. The median 
time since first diagnosis of SM was 25.9 months (range 
1.2–287.3 months). The median patient age was 52 years 
(range 29–79 years). The median time since diagnosis was 
similar in patients with ASM and those with ISM (25.9 
vs 27.4 months, respectively). At baseline, 36 patients 
(59.0 %) had a KIT D816V mutation, and 5 patients (8.2 %) 
had no KIT mutation; in 20 patients (32.8 %), KIT muta-
tion analysis was missing. All patients had at least 1 sam-
ple evaluated for KIT mutation status at any point during 
the study. Of the 25 patients with no or missing mutation 
data at baseline, 12 (48.0 %) subsequently tested positive 
for KIT D816V. Using data obtained at any point during 
the study, 48 patients (78.7 %) had a KIT D816V mutation, 
and 13 patients (21.3 %) did not; no patients had a D816Y 
mutation. All of the 53 patients tested for the FIP1L1–
PDGFRα fusion at any time during the study had a negative 
result.
Baseline characteristics of these retrospectively deter-
mined subgroups reflected differences in overall disease 
status. For example, the proportion of patients with WHO 
performance status of ≥2 was higher in the ASM group 
(18.9 %) than in the ISM group (5.3 %). Fewer patients 
in the ASM group had no prior treatment for SM (40.5 vs 
52.6 % in the ISM group). Baseline tryptase levels were 
generally higher in the ASM group (27.3 % of patients had 
AML acute myeloid leukemia, AHNMD associated clonal hematologic non–mast cell lineage disease, ANC absolute neutrophil count, ASM 
aggressive systemic mastocytosis, ISM indolent systemic mastocytosis, MCL mast cell leukemia, SM systemic mastocytosis, WHO World Health 
Organization
a Includes 3 patients with MCL, 1 patient with SM-AHNMD (responder, incomplete remission), and 1 patient with SM-AML
b Patient withdrew consent and was discontinued from the trial on study day 34
c Based on bone marrow or peripheral blood samples taken at baseline
d Symptoms were categorized as follows: constitutional symptoms—weight loss, fever, chills, night sweats, fatigue, lethargy, nausea, vomiting, 
and diarrhea; cutaneous symptoms—pruritus, flushing, urticaria, angioedema, erythema, atopic dermatitis, rashes, systemic lupus erythematosus, 
herpes zoster, and skin mastocytosis; mediator-related symptoms—headache, dizziness/lightheadedness, migraine, vertigo, and syncope/presyn-
cope
Table 1  continued
Total ASM ISM Othera
All patients  
(N = 61)




All patients  
(n = 19)
All patients  
(n = 5)
 ANC (×109/L)
  <2 4 (6.6) 3 (8.1) 1 (12.5) 0 1 (20.0)
  2–7 47 (77.0) 28 (75.7) 5 (62.5) 16 (84.2) 3 (60.0)
  >7 10 (16.4) 6 (16.2) 2 (25.0) 3 (15.8) 1 (20.0)
 Platelet count (×109/L)
  <100 9 (14.8) 8 (21.6) 2 (25.0) 0 1 (20.0)
  100–400 50 (82.0) 27 (73.0) 5 (62.5) 19 (100) 4 (80.0)
  >400 2 (3.3) 2 (5.4) 1 (12.5) 0 0
 Bone marrow mast cell infiltration (%) (n = 55) (n = 34) (n = 7) (n = 17) (n = 4)
  <10 24 (43.6) 16 (47.1) 4 (57.1) 8 (47.1) 0
  10–20 15 (27.3) 9 (26.5) 2 (28.6) 5 (29.4) 1 (25.0)
  >20–30 5 (9.1) 2 (5.9) 1 (14.3) 3 (17.6) 0
  >30 11 (20.0) 7 (20.6) 0 1 (5.9) 3 (75.0)
Symptoms at baseline, n (%)d
 Urticaria 20 (32.8) 11 (29.7) 2 (25.0) 8 (42.1) 1 (20.0)
 Cutaneous symptoms 36 (59.0) 21 (56.8) 5 (62.5) 13 (68.4) 2 (40.0)
 Constitutional symptoms 33 (54.1) 22 (59.5) 3 (37.5) 8 (42.1) 3 (60.0)
 Mediator-related symptoms 31 (50.8) 20 (54.1) 5 (62.5) 9 (47.4) 3 (60.0)
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levels >200 ng/mL at baseline vs 12.5 % of patients in the 
ISM group). Anemia (hemoglobin level <10 g/dL), neutro-
penia (ANC <2 × 109/L), and thrombocytopenia (platelet 
count <100 × 109/L) were all more common in the ASM 
group than the ISM group (18.9 vs 0 %, 8.1 vs 0 %, and 
21.6 vs 0 %, respectively). The proportion of patients with 
bone marrow mast cell infiltration >30 % was also greater 
in the ASM group (20.6 %) than in the ISM group (5.9 %). 
Constitutional and mediator-related symptoms were more 
common in patients with ASM than in those with ISM 
(59.5 vs 42.1 and 54.1 vs 47.4 %, respectively), whereas 
urticarial and cutaneous symptoms were less common in 
the ASM group than the ISM group (29.7 vs 42.1 and 56.8 
vs 68.4 %, respectively).
Patient disposition and drug exposure
At the time of data cutoff (January 19, 2009), 8 patients 
had entered the extension study, and 53 patients had dis-
continued treatment (Table 2). The most common reason 
for discontinuation was AEs [n = 18 (29.5 %)]. Diarrhea, 
fatigue, and pain in extremity (3.3 % each) were the AEs 
most frequently leading to discontinuation. Eleven patients 
(18.0 %) experienced grade 3/4 AEs leading to discon-
tinuation. Each grade 3/4 AE occurred in only 1 patient. 
Eleven patients (18 %) had disease progression that led to 
discontinuation.
The median total daily dose of nilotinib received was 
close to the planned total daily dose of 800 mg [787.6 mg 
(range 318.9–953.5 mg)]. Median treatment duration 
was 232 days (range 3–1274 days). One-third of patients 
(32.8 %) were treated with nilotinib for a minimum of 
12 months, and 18.0 % received nilotinib for ≥24 months. 
Nearly half of all patients had a nilotinib dose reduction 
[n = 29 (47.5 %)] and/or interruption [n = 30 (49.2 %)]. 
The most common AEs requiring dose adjustment or inter-
ruption were nausea (16.4 %), diarrhea (14.8 %), vomiting 
(13.1 %), and fatigue (6.6 %). Dose interruptions lasted 
a median of 13.5 days (range 2–47 days). Interruptions 
constituted a median of 5.1 % of total dosing days (range 
0.2–42 %).
Efficacy and characteristics of responders in the ASM 
subgroup
In the ASM subgroup, a minor response or better was 
achieved by 8 patients (21.6 %) receiving nilotinib 400 mg 
twice daily, all of whom had a KIT D816V mutation at any 
time during the study (Table 3). Incomplete remission and 
pure clinical response were each achieved by 1 patient, 
while good partial response and minor response were each 
achieved by 3 patients (8.1 %). Stable disease was observed 
in 16 patients (43.2 %), and 3 patients (8.1 %) had disease 
progression as their best response. Ten patients were not 
evaluable for response, in part because some patients did 
not have baseline C-finding data, which were collected ret-
rospectively after response criteria for ASM became avail-
able (Gotlib et al. 2013).
In patients with ASM, responses were evaluated based 
on baseline KIT D816V mutation status (Table 3). Of 22 
patients with mutated KIT D816V at baseline, 6 (27.3 %) 
achieved an overall response to treatment, including 1 pure 
clinical response (4.5 %), 2 good partial responses (9.1 %), 
and 3 minor responses (13.6 %). Nine patients with a base-
line KIT D816V mutation (40.9 %) had stable disease, and 
1 patient (4.5 %) had disease progression. Of 15 patients 
with no baseline mutation or missing KIT D816V status, 2 
(13.3 %) had an overall response to treatment [including 1 
incomplete remission (6.7 %) and 1 good partial response 
(6.7 %)], 46.7 % had stable disease, and 13.3 % had disease 
progression as their best response. However, 7 of 15 patients 
with no or missing KIT mutation status at baseline tested 
positive for a D816V mutation in subsequent analyses.
The baseline characteristics of ASM responders were 
largely similar to those of the total ASM population, but 
some differences were observed (Table 1). For instance, all 
responders had the major criterion for SM (vs 78.4 % of 
all patients). Further, the proportion of patients with con-
stitutional symptoms was lower in responders than in the 
total ASM population (37.5 vs 59.5 %), and the proportion 
of patients with bone marrow mast cell infiltration <10 % 
was higher in responders (62.5 vs 47.1 %). The median 
Table 2  Patient disposition
a Enrolled in the ongoing extension portion of the study at the time 
of data cutoff
b One patient underwent dose interruption for thrombocytopenia, 
which did not resolve within the time period specified by the proto-
col; the patient was therefore removed from the study by the sponsor. 
The other 4 patients were discontinued due to unsatisfactory response 
(all had stable disease)
c Only includes patients for whom death was cited as the primary 
reason for discontinuation of study treatment
n (%)
Total patients treated 61 (100)
Entered extension studya 8 (13.1)
Discontinued core treatment 53 (86.9)
Adverse event(s) 18 (29.5)
Withdrew consent 15 (24.6)
Disease progression 11 (18.0)
Administrative problemsb 5 (8.2)
Abnormal test procedure result(s) 1 (1.6)
Protocol violation 1 (1.6)
Lost to follow-up 1 (1.6)
Deathc 1 (1.6)
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time since SM diagnosis was longer for responders than 
for all patients (34.5 vs 25.9 months), and presence of the 
KIT D816V mutation at any time was more common in 
responders (100 %) compared with the total ASM popula-
tion (78.4 %).
Description of response as measured by changes 
in laboratory parameters
In responders in the ASM subgroup, the parameter with the 
highest degree of change was ANC; median best increase 
from baseline was 94.7 % (Fig. 1). Furthermore, when best 
values were compared with baseline values, the propor-
tion of mast cells found in bone marrow decreased 70.0 %. 
Moderate change was seen in platelet counts (43.5 % 
increase) and tryptase levels (29.8 % decrease). There was 
little change in hemoglobin and albumin levels during the 
study (increases of 11.5 and 15.1 %, respectively).
Because the ASM criteria for response cannot be used 
in patients with other SM subtypes, patients in other sub-
groups were evaluated based on changes in laboratory 
parameters. In the ISM subgroup (n = 17 evaluable at base-
line), the proportion of mast cells found in the bone marrow 
decreased 80 %, and ANC decreased by 64.6 % (Fig. 2). 
Platelet counts increased by 19.5 %. As in the ASM sub-
group, hemoglobin and albumin levels showed mini-
mal change during the study (increases of 4.3 and 4.5 %, 
respectively). The median tryptase level in the ISM group 
increased by 22.6 %; however, the interquartile range of 
tryptase levels at baseline and best value during the study 
showed a trend for decreasing tryptase levels.
Because patients in the “other” subgroup had different 
SM designations, patient laboratory values were evaluated 
individually rather than as a group (Fig. 3). All of these 
patients, except 1 patient with MCL (denoted as MCL-3 
in the figure), had a KIT D816V mutation at any time. In 
general, most patients in the “other” subgroup experienced 
improvements in albumin and neutrophil levels and platelet 
counts. The patient with SM-AML experienced a decrease 
in hemoglobin, while all other patients experienced an 
increase in hemoglobin during the study. Because of miss-
ing values, trends in mast cell infiltration and tryptase level 
in this population could not be determined.
Survival
During the study, 11 deaths occurred: 9 in the ASM subgroup 
and 2 in the “other” subgroup (both patients with MCL). 
Four deaths occurred during treatment or within 28 days of 
study drug discontinuation, while 7 deaths occurred during 
long-term follow-up. Ten deaths were due to disease pro-
gression, and 1 cause of death was listed as dyspnea and 
weakness. Of patients with KIT D816V mutations at baseline 
(n = 36) or at any time (n = 48), 5 deaths were reported. 
The rate of overall survival at 24 months was 81.2 % (95 % 
CI 70.6–91.8 %), with the median overall survival not yet 
reached after a median of 34.7 months of follow-up (Fig. 4).
Safety
All patients reported at least 1 AE, which was not unex-
pected given the severe nature of the underlying disease. 
The most frequent study drug-related AEs included nausea 
(39.3 %), headache (32.8 %), fatigue (29.5 %), diarrhea 
(27.9 %), vomiting (26.2 %), and pruritus (24.6 %; Table 4). 
Gastrointestinal and skin toxicities were consistent with the 
Table 3  Best responses in 
the ASM subgroup and by 
KIT D816V mutation status at 
baseline or at any time during 
the study
ASM aggressive systemic mastocytosis
a Includes 7 patients with ASM with no/missing mutation data at baseline
ASM 
(n = 37)
KIT D816V mutation at baseline KIT D816V mutation at 
any time
Yes (n = 22) No/missing (n = 15) Yesa (n = 29) No (n = 8)
Response (95 % CI), n (%)
 Overall response 8 (21.6) 6 (27.3) 2 (13.3) 8 (27.6) 0
  Complete remission 0 0 0 0 0
  Incomplete remission 1 (2.7) 0 1 (6.7) 1 (3.4) 0
  Pure clinical response 1 (2.7) 1 (4.5) 0 1 (3.4) 0
  Good partial response 3 (8.1) 2 (9.1) 1 (6.7) 3 (10.3) 0
  Minor response 3 (8.1) 3 (13.6) 0 3 (10.3) 0
 Absence of response 29 (78.4) 16 (72.7) 13 (86.7) 21 (72.4) 8 (100)
  Stable disease 16 (43.2) 9 (40.9) 7 (46.7) 14 (48.3) 2 (25.0)
  Progression 3 (8.1) 1 (4.5) 2 (13.3) 1 (3.4) 2 (25.0)
  Not evaluable 10 (27.0) 6 (27.3) 4 (26.7) 6 (20.7) 4 (50.0)
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overall safety profile for nilotinib (Kantarjian et al. 2007; 
Tasigna package insert. 2015). Newly occurring or worsen-
ing grade 3/4 hematologic laboratory abnormalities included 
thrombocytopenia (10.3 %), anemia (10.0 %), and neutrope-
nia (6.9 %; Table 5). The most frequent newly occurring or 
worsening grade 3/4 biochemical laboratory abnormalities 
included decreased serum phosphate (17.2 %), increased 
serum lipase (17.0 %), increased serum bilirubin (13.3 %), 
and increased serum alanine aminotransferase (10.2 %). 
Study drug-related SAEs of any grade were experienced by 
14 patients (23.0 %). Diarrhea (4.9 %), vomiting (3.3 %), 
and dehydration (3.3 %) were the only study drug-related 
SAEs that occurred in more than 1 patient. Patients were 
carefully monitored for cardiac changes occurring on study. 
A QTcF increase >60 ms from baseline occurred in two 
patients but did not result in treatment discontinuation in 
either patient. No patients had a QTcF >480 ms.
Discussion
SM is a heterogeneous disease. Consensus guidelines on 
the diagnosis and subclassification of patients with SM 
were published in 2007 (Valent et al. 2007) and have since 
been updated and refined by several groups, including the 
WHO (Pardanani and Tefferi 2010a, b; Valent et al. 2012; 
Horny et al. 2008). These criteria have established defini-
tive categories of SM distinguishable by their clinical 
presentation, histology, and growth characteristics: ISM, 
ISM with bone marrow involvement but no skin lesions, 
smoldering SM (SSM), SM-AHNMD, ASM, and MCL 
(Gotlib et al. 2013). These categories were established 
after the design of the current trial. Here, disease subtypes 
were determined retrospectively, and the study population 
included patients with a heterogeneous mixture of SM sub-
types, making interpretation of the data difficult.
Patients with different SM subtypes require differ-
ent types of treatment. Patients with ISM may not require 
cytoreductive therapy because their symptom burden is 
low (Valent et al. 2010). Traditional treatments for more 
advanced SM, including cladribine (Hermine et al. 2010) 
and IFN (Casassus et al. 2002), are sufficient to improve 
disease symptoms but have limited efficacy in reducing 
underlying disease burden (Lim et al. 2009a). Given the 
inadequacy of current treatment strategies, particularly with 
aggressive SM subtypes, and the role that KIT activation 
may play in the disease, the level of interest in targeted 
therapies for the treatment of SM has increased.
The high prevalence of the KIT D816V activating muta-
tion in patients with SM led to the development of KIT 
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Fig. 1  Improvements in laboratory parameters of responders in the ASM subgroup while on study
2055J Cancer Res Clin Oncol (2015) 141:2047–2060 
1 3
inhibitors for the treatment of this disease (Pardanani et al. 
2003). Imatinib is a KIT-targeted TKI that is approved for 
patients with multiple hematologic malignancies, including 
adult patients with ASM without the KIT D816V mutation 
or with unknown KIT mutational status (Gleevec package 
insert. 2015). However, imatinib has demonstrated only 
modest activity against the KIT D816V mutation in vitro 
and in the clinic (Lim et al. 2009a; Vega-Ruiz et al. 2009; 
Gleixner et al. 2006). For example, a study including 22 
patients with SM treated with imatinib demonstrated an 
ORR of 33.3 % in patients without the KIT D816V muta-
tion, 16.7 % in patients with this mutation, and 0 % in 
patients with missing mutation data (Lim et al. 2009a).
Here, we report the activity of nilotinib in patients 
with SM enrolled in an open-label registration trial. 
Patients with SM, with or without the KIT D816V muta-
tion, met the standard disease criteria for SM and had a 
clinical indication for treatment. Approximately half of 
the patients (47.5 %) had received no prior treatment for 
SM. Eight patients (21.6 %) in the ASM subgroup had a 
minor response or better to nilotinib. The safety profile of 
nilotinib in patients with SM was similar to that previously 
reported with nilotinib in other hematologic malignancies 
(Kantarjian et al. 2007; Tasigna package insert. 2015).
Although nilotinib has shown little inhibitory activity 
toward the KIT D816V/Y mutation in vitro (von Bubnoff 
et al. 2005; Verstovsek et al. 2006; Manley et al. 2010), 
the ORR in patients with ASM with the KIT D816V muta-
tion at any time was higher than that in patients without the 
mutation at baseline [8/29 (27.6 %) vs 0/8 (0 %), respec-
tively]. The mechanisms responsible for this are currently 
unknown. The D816V mutation shifts KIT from the inac-
tive conformation, to which imatinib and nilotinib bind, 
to its active conformation (Gajiwala et al. 2009; Weisberg 
et al. 2005). Nilotinib-mediated inhibition of KIT signal-
ing in nontransformed cells that support survival of malig-
nant cells (e.g., stromal cells, mast cells, macrophages) 
may provide some clinical benefit, even in patients with 
KIT D816V-mutated SM (Pittoni et al. 2011). In addition, 
nilotinib may be active against other KIT-dependent and 
-independent pathways involved in the development of 
SM (Gleixner et al. 2011; Schwaab et al. 2013). Additional 
studies are needed to further explore the pathogenesis of 
SM and to understand the mechanisms underlying the clini-
cal activity of nilotinib in SM. It also must be noted that 
20 patients did not have KIT mutation results available at 
baseline. Thus, response rates in patients with mutated KIT 
D816V vs unmutated KIT must be interpreted with caution.
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Fig. 2  Improvements in laboratory parameters in the ISM subgroup while on study
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Fig. 3  Improvements in laboratory parameters for each patient in the “other” subgroup while on study
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In the current study, all patients with ASM who 
responded met the major criterion for SM diagnosis (multi-
focal clusters of mast cells in the bone marrow) at baseline. 
During the study, the proportion of mast cells in the bone 
marrow in patients who responded decreased by 70.0 %, 
suggesting that nilotinib did have an effect on the underly-
ing disease in these patients. Likewise, serum tryptase level 
is a minor diagnostic criterion in SM and a strong meas-
ure of disease status. Elevated serum tryptase level can 
predict progression to more aggressive forms of disease 
(Kristensen et al. 2013) and has been shown to correlate 
with KIT D816V allele burden, a marker of disease sever-
ity (Matito et al. 2013). In the current study, the median 
tryptase level decreased by 29.8 % in responders with 
ASM. Thus, while the rate of response was not high, the 
quality of response in patients who did respond suggests 
that nilotinib may have clinical benefit in some patients. 
Improvements in laboratory parameters were also observed 
in the ISM and the “other” subgroups. However, these sub-
groups cannot be evaluated using standard ASM criteria 
due to differences in the underlying disease.
The current trial had several limitations. Current 
response criteria, developed after the design of this study, 
are based on the resolution of C-findings in patients with 
the aggressive subtype of SM (Gotlib et al. 2013). This 
study included patients less likely to have C-findings at 
baseline; 31.1 % of patients had ISM. Using C-findings as 
a measure of response may not be appropriate for patients 
with ISM. Also, because C-findings were collected retro-
spectively in this study, these data may not be complete. 
Furthermore, the minimum response duration in this study 
(4 weeks) was shorter than current response duration cri-
teria (12 weeks) (Gotlib et al. 2013), which may have 
increased the rates of response observed. For these reasons, 
the true magnitude of the clinical benefit of nilotinib in this 
population is difficult to determine, and it is possible that 
the response rates observed in this study may overestimate 
the true benefit of nilotinib in patients with advanced SM.
Previous studies have demonstrated a median overall 
survival of 24 months in patients with ASM (Lim et al. 
2009b; Fuller 2012). Despite a lack of response in the 
majority of patients in the current study, overall survival 
was 81.2 % at 24 months, with the median survival not yet 
reached after a median of 34.7 months of patient follow-
up. Thus, our data demonstrate that treatment with nilo-
tinib may provide some clinical benefit to patients with 
SM. It is also possible, as our retrospective interpretation of 
the study population suggests, that a sufficient number of 
patients with ISM were included who may have skewed the 
overall survival results in such a manner that the true bene-
fit is somewhat less than identified here. Additional studies 
will be necessary to determine whether nilotinib improves 
the long-term survival of patients with SM, including 
patients with ASM.
Several additional KIT-targeting TKIs are currently 
being investigated in patients with SM. Although the dual 
BCR-ABL/SRC TKI dasatinib inhibits the kinase activity 
of KIT D816V in vitro (Shah et al. 2006; Lombardo et al. 
2004) and has demonstrated efficacy in other myeloprolif-
erative neoplasms, such as CML (Kantarjian et al. 2010), 
it has displayed minimal activity in patients with SM (Ver-
stovsek et al. 2008). Data from a phase 2 study in patients 
with systemic or cutaneous mastocytosis (N = 25) treated 
Table 4  Most common study drug-related nonhematologic AEs 








Nausea 24 (39.3) 2 (3.3)
Headache 20 (32.8) 3 (4.9)
Fatigue 18 (29.5) 1 (1.6)
Diarrhea 17 (27.9) 4 (6.6)
Vomiting 16 (26.2) 2 (3.3)
Pruritus 15 (24.6) 1 (1.6)
Muscle spasms 13 (21.3) 2 (3.3)
Upper abdominal pain 12 (19.7) 1 (1.6)
Rash 10 (16.4) 1 (1.6)
Dizziness 8 (13.1) 1 (1.6)
Arthralgia 7 (11.5) 1 (1.6)
Bone pain 7 (11.5) 1 (1.6)
Myalgia 7 (11.5) 1 (1.6)
Peripheral edema 7 (11.5) 1 (1.6)
Table 5  Newly occurring or worsening grade 3/4 laboratory abnor-
malities (occurring in ≥5 % of evaluable patients)
AE adverse event, ALT alanine aminotransferase
a Patients evaluable postbaseline who had <grade 4 at baseline
Laboratory abnormality n/Na (%)
Hematologic
 Thrombocytopenia 6/58 (10.3)
 Anemia 6/60 (10.0)
 Neutropenia 4/58 (6.9)
Nonhematologic
 Decreased serum phosphate 10/58 (17.2)
 Increased serum lipase 9/53 (17.0)
 Increased serum bilirubin (total) 8/60 (13.3)
 Increased serum ALT 6/59 (10.2)
 Decreased sodium 4/60 (6.7)
 Hyperglycemia 3/56 (5.4)
 Decreased serum albumin 3/58 (5.2)
 Decreased potassium 3/60 (5.0)
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with the KIT/LYN kinase inhibitor masitinib, however, 
demonstrated an ORR of 56.0 % and modest improve-
ments in symptoms and quality-of-life measurements after 
12 weeks of treatment (Paul et al. 2010).
The multikinase inhibitor midostaurin has also demon-
strated potent in vitro activity against KIT D816V (Gleixner 
et al. 2006; Weisberg et al. 2002; Fabbro et al. 2000) as well 
as activity in patients with advanced SM with this mutation 
(Gotlib et al. 2010). Phase 2 data in a cohort of 26 patients 
with advanced SM demonstrated an ORR of 69.2 %, and 
the presence of the KIT D816V mutation was significantly 
associated with achievement of a major response (Gotlib 
et al. 2010). Another phase 2 study used central adjudica-
tion to identify patients with ASM or MCL, thereby pro-
ducing a homogenous population of patients with advanced 
SM according to the current definitions (Gotlib et al. 2014). 
In this trial, which evaluated midostaurin in patients with 
ASM or MCL (n = 89), high rates of durable responses and 
good tolerability were observed. The ORR was 60 % (45 % 
major response and 15 % partial response). The ORR was 
63 % in patients with the KIT D816V mutation (46 of 73) 
and 44 % in patients without it (7 of 16). With a median fol-
low-up of 26 months, the median duration of response was 
24 months (range 11 months—not evaluable), and median 
OS was 29 months (range 18 months—not evaluable). Fur-
ther, improvements in symptoms and quality-of-life meas-
ures were observed in all patients across all reported scales.
KIT-targeting TKIs may also be effective when used in 
combination with other treatments, such as chemotherapy. 
Treatment with the TKI dasatinib and standard chemo-
therapy induced hematologic remission and decreased the 
levels of KIT D816V in the mast cells of a patient with 
SM-AML (Ustun et al. 2009). Combined inhibition of 
KIT and its downstream effectors, such as PI3K or STAT5, 
may also be an effective strategy in SM (Harir et al. 2008; 
Buet et al. 2012). Several clinical trials are evaluating addi-
tional agents in patients with SM, including the interleukin 
2-diphtheria toxin fusion protein denileukin diftitox and the 
mechanistic target of rapamycin (mTOR) inhibitor everoli-
mus (US National Institutes of Health 2015).
Despite its limitations, this study provides additional 
information about this rare disease and illustrates the 
importance of enrolling only patients who meet strict eligi-
bility criteria in prospective trials to ensure consistency of 
populations across studies. Data from the present analysis 
demonstrated that nilotinib has a safety profile that is con-
sistent with that seen in previous reports and has modest 
clinical activity in patients with SM, particularly patients 
with the KIT D816V mutations who otherwise have lim-
ited treatment options. Nilotinib, either alone or in combi-
nation with other agents, may have a role in the treatment 
of these patients. However, other TKIs, which in more 
recent trials have shown higher rates of response in patients 
with advanced SM, may provide more clinical benefit for 
patients with more aggressive disease. Future studies of SM 
should use the most recent disease classification definitions 
to generate homogeneous patient populations and more 
robust data sets. Furthermore, identification of SM patient 
subgroups mostly likely to benefit from nilotinib may be an 
important approach in future studies of SM.
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